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Abstract 
Background: Carbamazepine is an antiepileptic drug used widely for the treatment of epileptic seizures and 
neuropathic pain. Several malformations in humans, mainly neural tube defects, have been reported as a 
consequence of its use during pregnancy. The association between maternal use of carbamazepine and 
congenital eye malformations is not very well understood. 
Objective: The purpose of this study was to examine this association after intraperitoneal injection of 
car bamazepine during the period of organogenesis in mice. 
Methods: Balb/c timed-pregnant mice were divided into 4 experimental and control groups. Two 
e xperimental groups received daily intraperitoneal injections of 15 mg/kg (group I) or 30 mg/kg (group 
II) of carbamazepine on gestational days 6 to 15. Two control groups received normal saline or Tween 20 
(polysorbate 20). Dams underwent Cesarean section on gestational day 18 and embryos were harvested. 
External examination for eye malformations, routine histological processing of malformed fetuses to study 
eye morphology, and skeletal staining were performed. 
Results: The mean weight and crown-rump of the fetuses in both experimental groups were significantly 
reduced compared with those of the control groups. Various malformations were detected such as brach-
ygnathia, calvarial deformity, vertebral deformity, short tail, and brachydactyly. Premature opening of one 
or both eyes with mild to severe exophthalmos occurred in the 2 experimental groups. Deformed lens, 
retinal folds with undeveloped layers, and corneal folds with absence of surface epithelium were detected 
in both experimental groups. 
Conclusions: This study, to the best of our knowledge, showed for the first time that intraperitoneal admin-
istration of carbamazepine at clinically comparable doses during organogenesis can induce several eye 
malformations in mice. The implication of these results needs to be considered when carbamazepine is 
administered during human pregnancy. 
Keywords: Carbamazepine; ocular malformations; mice; teratogenicity; pregnancy 
Introduction trigeminal neuralgia. It is also used off label for a vari-
ety of indic ations, including attention-deficit hyper-
Carbamazepine (CBZ) is an anticonvulsant and activity disorder (ADHD), schizophrenia, phantom 
mood-stabilizing drug used primarily in the treat- limb s yndrome, paroxysmal extreme pain disorder, 
ment of epilepsy and bipolar disorder, as well as and posttraumatic stress disorder. It is administered 
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mainly by the oral route at doses between 200 and 
1,600 mg/day. It is highly effective for partial-onset 
seizures, including cryptogenic and symptomatic 
partial seizures. It also has demonstrated good effi-
cacy in the treatment of generalized tonic-clonic 
seizures, trigeminal neuralgia, neuropathic pain, 
and mood disorders. This drug is highly effective, 
well tolerated, and, compared with other antiepilep-
tic drugs (AEDs), considered relatively safe during 
pregnancy; therefore, it is used regularly by pregnant 
women. Chemically, CBZ is a neutral, lipid-soluble 
compound that can easily pass the blood–brain bar-
rier and other membranes in the body [1,2]. In recent 
comparative clinical trials, it has been demonstrated 
that CBZ is equally efficacious with, but is less toxic 
than, phenobarbital, phenytoin, primidone, or val-
proic acid [3]. 
Antiepileptic treatment during pregnancy is 
associated with a 2- to 3-fold increase in the rate of 
major congenital anomalies, mainly congenital heart 
defects, cleft lip, and cleft palate; anomalies of the 
urinary tract; and syndromes of dysmorphism and 
developmental disability [2]. There is some contro-
versy concerning the teratogenic effects of CBZ, but 
most investigators believe that malformations asso-
ciated with maternal use of CBZ can be commonly 
divided into major malformations such as craniofa-
cial defects, heart defects, and neural tube defects 
and minor anomalies such as growth retardation, 
developmental delay, and hyperplasia of the nails or 
distal phalanges [2,4]. 
The association between maternal use of CBZ and 
congenital eye malformations is a subject that has 
emerged the field of teratology in the last several 
years [5]. Sutcliffe et al. have reported 4 unrelated 
cases of congenital eye malformations in newborns 
whose mothers were taking CBZ monotherapy 
during at least the first 2 months of pregnancy [6]. 
However, some investigators did not find any asso-
ciation between these congenital eye malformations 
and prenatal CBZ exposure [7]. 
The objective of this investigation was to show 
the spectrum of malformations of CBZ at clinically 
com parable doses administered intraperitoneally (IP) 
during organogenesis in Balb/c mice. 
Materials and methods 
Animals, drugs, and treatment 
Virgin female Balb/c mice, weighing 28–30 grams 
(8–9 weeks old) were used in this study. The animals 
were maintained in a climate-controlled room under 
a 12-hour alternating light/dark cycle (0900–2100 
hours in light), 20.1°C to 21.2°C temperature, and 
50% to 55.5% relative humidity. Dry food pellets 
and water were provided ad libitum. After 2 weeks 
of acclimation to the diet and the environment, 
3 females were caged overnight with a male of the 
same strain. The presence of a vaginal plug the fol-
lowing morning confirmed that mating had taken 
place and was designated as gestational day (GD) 
0. Maternal weights were measured daily through-
out the experiment. Dams were observed for any 
signs of clinical toxicity. Forty pregnant mice were 
randomly divided into 2 experimental groups (10 
mice in each group) receiving 15 mg/kg/day of CBZ 
in experimental group I and 30 mg/kg/day of CBZ in 
experimental group II, and 2 control groups (10 mice 
in each group) receiving normal saline (negative con-
trol) or Tween 20 (polysorbate 20; vehicle control). 
The selected doses of CBZ were comparable to the 
human therapeutic doses in the clinic (15 mg/kg). 
Dams received CBZ or vehicles daily from GDs 6 to 15 
by IP injection. CBZ powder was obtained from Mehr 
Darou Pharmaceutical Company in Tehran, Iran. 
Tween 20 (Merck, Darmstadt, Germany) was used as 
a vehicle to help solubility. Approval for this study was 
gained from the Animal Care and Ethics Committee 
of Birjand University of Medical Sciences. 
Fetal assessment 
On GD 18, the pregnant mice were sacrificed under 
ether anesthesia, the uterus was opened, the umbilical 
cord was cut close to the fetus, the uterus was removed 
and uterine weight was recorded, and the corpora 
lutea was counted and recorded. Each fetus and pla-
centa were then weighed. Fetuses were assessed as 
either alive or dead and any resorption was noted; live 
fetuses were then euthanized by hypothermia. The 
crown-rump of each fetus was measured and each 
fetus was examined externally for malformations or 
deviations from normal growth. 
Skeleton and tissue staining 
Malformed fetuses were selected for double-staining 
of the skeleton. Fetuses were fixed for 3 days in 95% 
ethanol and then double-stained with alizarin red 
and alcian blue [8,9] with some modifications, and 
examined for skeletal anomalies. For tissue stain-
ing, fetuses with eye malformations were selected. 
The heads were removed and fixed in 10% neutral 
formalin solution. After fixation, routine processes 
of tissue preparation such as dehydration, clear-
ing, and infiltration were performed and specimens 
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were embedded in paraffin. The paraffin blocks were 
trimmed and thin serial sections (3–5 micrometers) 
were cut with a Zeiss rotary microtome (Zeiss, Jena, 
Germany). Some sections were randomly selected 
and stained with hematoxylin and eosin. 
Statistics 
The unit of analysis was the embryo, and the differ-
ences between the control groups and the treated 
groups were reported as mean ± standard deviation 
(SD). Analysis of variance (ANOVA) and Tukey’s test 
were used to evaluate corpora lutea, implantations, 
and fetal body weight. Resorbed embryos and external 
malformations were analyzed using χ2  test when the 
frequency of each category was 5 or more for resorp-
tion or external malformations, and with Fisher’s 
direct probability test for other cases. Differences 
were considered significant at p < 0.05. 
Results 
Maternal observations, body weight, and food 
consumption 
All females survived to scheduled study termination 
on GD 18. There were no postmortem findings judged 
to be treatment-related. There were no significant dif-
ferences in absolute maternal body weight in any of 
the treatment groups at any time during the study. 
No significant changes in maternal body weight gain 
were observed in any treatment group during the 
overall gestational period (GDs 0–18). There were 
no significant changes in mean food consumption 
between the experimental groups and control groups 
(data not shown). 
Reproductive parameters 
Findings upon cesarean section on GD 18 are shown 
in Table 1. The mean numbers of corpora lutea 
and implants were comparable among all groups. 
CBZ exposure resulted in statistically significant 
increase in late resorptions in both treatment groups 
compared with the control groups as analyzed in 
the compared litters (Table 1). The mean fetal body 
weights of both experimental groups I (0.72 ± 0.20 g) 
and II (0.68 ± 0.21 g) were significantly reduced 
compared with those of the vehicle and nega-
tive control groups (1.14 ± 0.19 g and 1.22 ± 0.18 g, 
respectively). The crown-rump lengths of live fetuses 
were also reduced significantly in both experimen-
tal groups as compared with both control groups 
(Table 1). 
The presence of external malformations such as 
brachygnathia (mandibular hypoplasia), open eye-
lid, calvarial deformity (such as frontal bone defect), 
vertebral deformity (such as scoliosis), short tail, and 
brachydactyly was considered related to CBZ admin-
istration (Table 2). A few fetuses showed severe growth 
retardation (Figure 1A). 
Fetuses with ocular anomalies 
Premature opening of one or both eyelids with mild to 
severe exophthalmos occurred in 8.6% and 7.5% of the 
fetuses in experimental groups I and II, respectively. 
Malformations were often bilateral and approximately 
symmetrical (Figure 1B). Histological findings showed 
that exposed corneal epithelium was folded and often 
attenuated. The lens was small and deformed and 
the retina had a folded pattern with undifferentiated 
layers (Figure 1C). Fetuses that presented eye, cal-
varial, and vertebral malformations were also smaller. 
Table 1. Cesarean section parameters on gestational day 18 in Balb/c mice treated with CBZ. 
Parameters 
Control groups Experimental groups (CBZ) 
Tween 20 NS 15 mg/kg 30 mg/kg 
Litters No.  10 10 10  10 
Corpora lutea No. fetuses examined 148 150 146 144 
Mean ± SD 14.8 ± 1.5 15.0 ± 2.0 14.6 ± 1.8 14.4 ± 1.8 
Implants No. fetuses examined 141 143 139 133 
Mean ± SD 14.1 ± 1.6 14.3 ± 1.8 13.9 ± 2.2 13.3 ± 2.1 
Live fetuses No. (%) 140 (99.3) 143 (100) 128 (92.09) 120 (90.23) 
Resorptions No. (%) 1 (0.7) 0 (0) 11 (7.91)a 13 (9.77)a 
Fetal body weight (g) Mean ± SD 1.14 ± 0.19 1.22 ± 0.18 0.72 ± 0.20b 0.68 ± 0.21b 
Crown-rump length of live 
fetuses(mm) 
Mean ± SD 22.9 ± 1.9 23.6 ± 1.9 18.2 ± 1.5b 17.7 ± 2.1b 
ap < 0.05 vs. control. 
bp < 0.01 vs. control. 
CBZ = carbamazepine; NS = normal saline; SD = standard deviation. 
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Skeletal staining of these malformed fetuses revealed 
some skeletal anomalies such as short, kinked tail and 
hypoplastic mandible (Figure 1D), scoliosis, wavy ribs, 
supernumerary ribs, and clinodactyly. 
Discussion 
Women who have used CBZ during pregnancy, 
es pecially during the first trimester, have a 
higher risk of neural tube defects (0.6%–1.7%) 
[10]. Furthermore, it has been reported that CBZ 
induces a pattern of minor anomalies and a delay 
in development in offspring [11] and may result in a 
“ carbamazepine syndrome” characterized by facial 
dysmorphic features and mild developmental dis-
ability [12]. In this study, we focused on the fetuses 
that had eye malformations, most notably open eye 
malformations, as it was the most prevalent eye 
malformation. 
In our study, decreases in fetal body weight and 
crown-rump length and increases in resorptions 
and malformations were seen in both CBZ-treated 
groups compared with the control groups; similar 
findings were reported in other studies [2,13–16]. 
External and skeletal malformations, including 
opened eyes, brachygnathia, vertebral and calvarial 
deformities, brachydactyly, and short tail, were seen 
in both treated groups (doses of 15 and 30 mg/kg). 
Furthermore, a few fetuses (4%–6%) in both treated 
groups had a malformation that could be described 
as severe growth retardation. 
The association between CBZ use by the mother 
during pregnancy and congenital eye malforma-
tions in the newborn in experimental studies is 
a relatively new subject in teratology. Although 
some clinical case reports have outlined this asso-
ciation, other experimental studies did not find 
any cases that showed this relation. Sutcliffe et al. 
A B 
C D 
Figure 1. A: Brachygnathia, open eyelid, calvarial deformity, 
scoliosis and brachydactyly as a result of CBZ administration are 
shown. B: Exophthalmos (arrrow) in an embryo in the CBZ-treated 
group. C: Deformity of lens and retina undifferentiation (arrow) 
in an embryo from the CBZ-treated group. D: Wavy ribs, scolio-
sis, supernumerary ribs and hypoplastic mandible are seen in this 
embryo as a result of CBZ administration. 
Table 2. External malformations in Balb/c mice treated with CBZ. 
Parameters 
Control groups Experimental groups (CBZ) 
Tween 20 NS 15 mg/kg 30 mg/kg 
Litters No. 10 10 10 10 
Fetuses examined No. 140 143 128 120 
Open eyes No. (%) littersa 0 (0) 0 (0) 2 (20) 3 (30) 
No. (%) fetusesb 0 (0) 0 (0) 11 (8.59)c 9 (7.50)c 
Brachygnathia No. (%) litters 0 (0) 0 (0) 4 (40)c 5 (50)c 
No. (%) fetuses 0 (0) 0 (0) 10 (7.81)c 14 (11.66)c 
Vertebral deformity No. (%) litters 0 (0) 0 (0) 1 (10) 4 (40)c 
No. (%) fetuses 0 (0) 0 (0) 2 (1.5) 9 (7.50)c 
Calvarial deformity No. (%) litters 0 (0) 0 (0) 4 (40)c 4 (40)c 
No. (%) fetuses 0 (0) 0 (0) 9 (7.03)c 13 (10.83)c 
Brachydactyly No. (%) litters 0 (0) 0 (0) 5 (50)c 5 (50)c 
No. (%) fetuses 0 (0) 0 (0) 17 (13.28)c 20 (16.6)c 
Severe malformation No. (%) litters 0 (0) 0 (0) 4 (40)c 3 (30) 
No. (%) fetuses 0 (0) 0 (0) 8 (6.25)c 5 (4.16)c 
Short tail No. (%) litters 0 (0) 0 (0) 3 (30) 4 (40)c 
No. (%) fetuses 0 (0) 0 (0) 13 (10.15)c 11 (9.16)c 
aNo. litters = number of litters having fetuses with the finding (percentage of total litters). 
bNo. fetuses = number of fetuses with the finding (percentage of total fetuses). 
cp < 0.05 vs. control. 
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have reported 4 unrelated cases of congenital eye 
malformations: bilateral anophthalmia (1 case), 
bilateral microphthalmia (2), and unilateral optic 
nerve coloboma (1). These occurred in the off-
spring of 4 different mothers who were taking CBZ 
monotherapy at doses between 200 and 600 mg/day 
during at least the first 2 months of pregnancy [6]. 
Two of these children had low birth weight and height 
at birth. Furthermore, these children showed reduc-
tion in corneal diameter and m icrospherical lens. In 
the current study, we also found similar findings in 
mouse fetuses that had open eye malformations. In 
an investigation of the visual and ocular outcomes 
of 43 children exposed to prenatal AEDs, the most 
common of which was CBZ, 2 children presented 
with severe microphthalmia and one with unilateral 
optic disk coloboma [5]. In another study, bilateral 
anophthalmia due to prenatal CBZ exposure was 
reported [17]. 
Conversely, some studies have not shown clear 
evidence of an association between CBZ use dur-
ing pregnancy and anophthalmia, microphthalmia, 
or coloboma of the iris or optic disk. Between 1981 
and 1999, a total of 288,094 births (live births and 
stillbirths) took place in the northern Netherlands, 
and 7,348 fetuses or children with at least 1 con-
genital anomaly were registered. Among these chil-
dren, 77 cases with 1 or more eye anomalies were 
recorded. These included 57 cases of anophthalmia 
or microphthalmia, 27 cases of coloboma of the 
iris, 6 cases of optic disk coloboma, and 3 cases of 
lens coloboma. CBZ use was not reported in any of 
these cases [7]. Among 8,005 cases of malformation 
registered with first-trimester drug exposure in the 
International Database on Malformations and Drug 
Exposure (MADRE), 46 cases were exposed to CBZ, 
but no association with any eye malformation was 
identified [18]. 
Based on our knowledge, our study is the first 
experimental study that has indicated an asso-
ciation between CBZ use and eye malformations. 
On the other hand, compared to our study, in 
most other animal studies higher oral doses of 
CBZ were used. For example, CBZ (200–600 mg/ 
kg) in rats increased resorption and skeletal 
and visceral malformations only at 600 mg/kg. 
However, its most marked effect at 200 mg/kg 
and 400 mg/kg was fetal body weight reduction [19]. 
Nevertheless, all the observed effects occurred at 
maternal serum concentrations substantially higher, 
up to 3 times those that are therapeutic for humans. 
To our knowledge, our study is the first to show that 
CBZ at clinically comparable doses administered 
during organogenesis caused embryonic malfor-
mations. This possibility could be explained by the 
route of administration (IP) that we chose to inves-
tigate. We believe this needs further investigation 
to help us better understand the mechanism of this 
observation. 
It is noteworthy that CBZ is metabolized through 
the arene oxide pathway by which xenobiotics can be 
hydroxylated through epoxide intermediates [20]. By 
covalent binding to macromolecules, epoxides may 
have mutagenic or teratogenic properties. The tera-
togenicity of CBZ epoxide has been demonstrated in 
a mouse model [21]. 
Furthermore, using an embryonic stem cell dif-
ferentiation system, analysis of tissue-specific gene 
markers showed that CBZ induced early endodermal 
and mesodermal differentiation but inhibited dif-
ferentiation of later developmental stages. CBZ also 
induced ectodermal development, and there was 
evidence of neural differentiation, as ES cells with an 
immature neuronal phenotype were observed [22]. 
Also, Steinhoff et al. [23] recommended the retina as 
a parallel model to study the mechanistic properties 
of anticonvulsant therapy on cortical and cerebral 
function, because the retina is ontogenetically part 
of the brain. 
Our results suggest further investigation to reveal 
the spectrum of eye malformations and mechanisms 
of this finding. 
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